发表在Diabetes Care的一项研究: 对象为前驱期糖尿病(prediabetes)和/或代谢综合征(and/or metabolic syndrome (MetS))人群,BMI在27~25 kg/m2之间。受试者接受为期108周的苯丁胺和托吡酯缓释剂治疗,同时进行生活方式调整。结果显示,这种治疗方案可显著降低体重,并降低发展为2型糖尿病的风险。
CONCLUSIONS PHEN/TPM ER plus lifestyle modification produced significant weight loss and markedly reduced progression to type 2 diabetes in overweight/obese patients with prediabetes and/or MetS, accompanied by improvements in multiple cardiometabolic disease risk factors.
原文链接:
Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release
注释:
苯丁胺 = phentermine
托吡酯缓释剂 = topiramate extended release (PHEN/TPM ER)
Fasting Plasma Glucose (FPG) = 空腹血糖
OGTT = oral glucose tolerance test (口服葡萄糖耐量试验)
HbA1c = Hemoglobin A1c (糖化血红蛋白)